

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2017 December 14; 23(46): 8109-8262



### REVIEW

- 8109** Relation of the IGF/IGF1R system to autophagy in colitis and colorectal cancer  
*Sipos F, Székely H, Kis ID, Tulassay Z, Múzes G*

### MINIREVIEWS

- 8120** Retreatment of patients with treatment failure of directacting antivirals: Focus on hepatitis C virus genotype 1b  
*Kanda T, Nirei K, Matsumoto N, Higuchi T, Nakamura H, Yamagami H, Matsuoka S, Moriyama M*

### ORIGINAL ARTICLE

#### Basic Study

- 8128** Structural shift of gut microbiota during chemo-preventive effects of epigallocatechin gallate on colorectal carcinogenesis in mice  
*Wang X, Ye T, Chen WJ, Lv Y, Hao Z, Chen J, Zhao JY, Wang HP, Cai YK*
- 8140** miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1  
*Liu XL, Cao HX, Wang BC, Xin FZ, Zhang RN, Zhou D, Yang RY, Zhao ZH, Pan Q, Fan JG*
- 8152** *In vivo* hepatic differentiation potential of human umbilical cord-derived mesenchymal stem cells: Therapeutic effect on liver fibrosis/cirrhosis  
*Zhang GZ, Sun HC, Zheng LB, Guo JB, Zhang XL*
- 8169** Pharmacokinetics and pharmacodynamics of Shengjiang decoction in rats with acute pancreatitis for protecting against multiple organ injury  
*Zhu L, Li JY, Zhang YM, Kang HX, Chen H, Su H, Li J, Tang WF*

#### Retrospective Cohort Study

- 8182** Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease  
*Spekhorst LM, Oldenburg B, van Bodegraven AA, de Jong DJ, Imhann F, van der Meulen-de Jong AE, Pierik MJ, van der Woude JC, Dijkstra G, D'Haens G, Löwenberg M, Weersma RK, Festen EAM; PARELSNOER Institute and the Dutch Initiative on Crohn and Coliti*

#### Retrospective Study

- 8193** Endoscopic ultrasound staging for early esophageal cancer: Are we denying patients neoadjuvant chemo-radiation?  
*Luu C, Amaral M, Klapman J, Harris C, Almhanna K, Hoffe S, Frakes J, Pimiento JM, Fontaine JP*

- 8200** Early gastric cancer frequently has high expression of KK-LC-1, a cancer-testis antigen  
*Futawatari N, Fukuyama T, Yamamura R, Shida A, Takahashi Y, Nishi Y, Ichiki Y, Kobayashi N, Yamazaki H, Watanabe M*

- 8207** Diagnostic classification of endosonography for differentiating colorectal ulcerative diseases: A new statistical method  
*Qiu EQ, Guo W, Cheng TM, Yao YL, Zhu W, Liu SD, Zhi FC*

**Clinical Trial Study**

- 8217** Characteristics of fecal microbial communities in patients with non-anastomotic biliary strictures after liver transplantation  
*Zhang J, Ren FG, Liu P, Zhang HK, Zhu HY, Feng Z, Zhang XF, Wang B, Liu XM, Zhang XG, Wu RQ, Lv Y*

**Observational Study**

- 8227** Balloon dilatation for treatment of hepatic venous outflow obstruction following pediatric liver transplantation  
*Zhang ZY, Jin L, Chen G, Su TH, Zhu ZJ, Sun LY, Wang ZC, Xiao GW*

**Prospective Study**

- 8235** Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China  
*Chen JM, Liu T, Gao S, Tong XD, Deng FH, Nie B*

**CASE REPORT**

- 8248** Are liver nested stromal epithelial tumors always low aggressive?  
*Meletani T, Cantini L, Lanese A, Nicolini D, Cimadamore A, Agostini A, Ricci G, Antognoli S, Mandolesi A, Guido M, Alaggio R, Giuseppetti GM, Scarpelli M, Vivarelli M, Berardi R*

- 8256** Combined thoracoscopic and endoscopic surgery for a large esophageal schwannoma  
*Onodera Y, Nakano T, Takeyama D, Maruyama S, Taniyama Y, Sakurai T, Heishi T, Sato C, Kumagai T, Kamei T*

**LETTER TO THE EDITOR**

- 8261** Extended pelvic side wall excision for locally advanced rectal cancers  
*Shaikh IA, Jenkins JT*

**ABOUT COVER**

Editorial board member of *World Journal of Gastroenterology*, Antonio Macri, MD, Associate Professor, Department of Human Pathology, University of Messina, Messina 98125, Italy

**AIMS AND SCOPE**

*World Journal of Gastroenterology* (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7<sup>th</sup>, 14<sup>th</sup>, 21<sup>st</sup>, and 28<sup>th</sup> each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

**INDEXING/ABSTRACTING**

*World Journal of Gastroenterology* (*WJG*) is now indexed in Current Contents<sup>®</sup>/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch<sup>®</sup>), Journal Citation Reports<sup>®</sup>, Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports<sup>®</sup> cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29<sup>th</sup> among 79 journals in gastroenterology and hepatology (quartile in category Q2).

**FLYLEAF**

I-IX Editorial Board

**EDITORS FOR THIS ISSUE**

Responsible Assistant Editor: *Xiang Li*  
 Responsible Electronic Editor: *Yu-Jie Ma*  
 Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Ze-Mao Gong*  
 Proofing Editorial Office Director: *Jin-Lei Wang*

**NAME OF JOURNAL**  
*World Journal of Gastroenterology*

**ISSN**  
 ISSN 1007-9327 (print)  
 ISSN 2219-2840 (online)

**LAUNCH DATE**  
 October 1, 1995

**FREQUENCY**  
 Weekly

**EDITORS-IN-CHIEF**  
**Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon**, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

**Stephen C Strom, PhD, Professor**, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

**Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology**, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

**EDITORIAL BOARD MEMBERS**  
 All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

**EDITORIAL OFFICE**  
 Jin-Lei Wang, Director  
 Ze-Mao Gong, Vice Director  
*World Journal of Gastroenterology*  
 Baishideng Publishing Group Inc  
 7901 Stoneridge Drive, Suite 501,  
 Pleasanton, CA 94588, USA  
 Telephone: +1-925-2238242  
 Fax: +1-925-2238243  
 E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
 Help Desk: <http://www.fjpublishing.com/helpdesk>  
<http://www.wjgnet.com>

**PUBLISHER**  
 Baishideng Publishing Group Inc  
 7901 Stoneridge Drive, Suite 501,  
 Pleasanton, CA 94588, USA  
 Telephone: +1-925-2238242  
 Fax: +1-925-2238243  
 E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
 Help Desk: <http://www.fjpublishing.com/helpdesk>  
<http://www.wjgnet.com>

**PUBLICATION DATE**  
 December 14, 2017

**COPYRIGHT**  
 © 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
 All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

**INSTRUCTIONS TO AUTHORS**  
 Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

**ONLINE SUBMISSION**  
<http://www.fjpublishing.com>

## Basic Study

***In vivo* hepatic differentiation potential of human umbilical cord-derived mesenchymal stem cells: Therapeutic effect on liver fibrosis/cirrhosis**

Guo-Zun Zhang, Hui-Cong Sun, Li-Bo Zheng, Jin-Bo Guo, Xiao-Lan Zhang

Guo-Zun Zhang, Hui-Cong Sun, Li-Bo Zheng, Jin-Bo Guo, Xiao-Lan Zhang, Department of Gastroenterology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China

Guo-Zun Zhang, First Department of Gastroenterology, Cangzhou Central Hospital, Cangzhou 061001, Hebei Province, China

Hui-Cong Sun, Department of Internal Medicine, Ningbo Women and Children's Hospital, Ningbo 315012, Zhejiang Province, China

**Author contributions:** Zhang GZ and Sun HC substantially contributed to the conception and design of the study and the acquisition, analysis and interpretation of the data; all authors drafted the article, made critical revisions related to the intellectual content of the manuscript, and approved the final version of the article to be published; Zhang GZ and Sun HC contributed equally to this manuscript.

**Institutional review board statement:** The study was reviewed and approved by the Hebei Medical University Institutional Review Board.

**Institutional animal care and use committee statement:** All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Experimental Animal Center of Hebei Medical University (No. 911102).

**Conflict-of-interest statement:** We declare that there are no conflicts of interest to disclose.

**Data sharing statement:** Technical appendix, statistical code, and data set available from the corresponding author at [xiaolanzh@126.com](mailto:xiaolanzh@126.com). Participants gave informed consent for data sharing.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,

which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to:** Xiao-Lan Zhang, MD, PhD, Professor, Department of Gastroenterology, The Second Hospital of Hebei Medical University, 215 West Heping Road, Shijiazhuang 050000, Hebei Province, China. [xiaolanzh@hb2h.com](mailto:xiaolanzh@hb2h.com)  
Telephone: +86-311-66007370

**Received:** March 27, 2017

**Peer-review started:** March 29, 2017

**First decision:** May 3, 2017

**Revised:** May 29, 2017

**Accepted:** August 9, 2017

**Article in press:** August 9, 2017

**Published online:** December 14, 2017

**Abstract****AIM**

To investigate the hepatic differentiation potential of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) and to evaluate their therapeutic effect on liver fibrosis/cirrhosis.

**METHODS**

A CCl<sub>4</sub>-induced liver fibrotic/cirrhotic rat model was used to assess the effect of hUC-MSCs. Histopathology was assessed by hematoxylin and eosin (H&E), Masson trichrome and Sirius red staining. The liver biochemical profile was measured using a Beckman Coulter analyzer. Expression analysis was performed using immunofluorescent staining, immunohistochemistry, Western blot, and real-time PCR.

## RESULTS

We demonstrated that the infused hUC-MSCs could differentiate into hepatocytes *in vivo*. Functionally, the transplantation of hUC-MSCs to CCl<sub>4</sub>-treated rats improved liver transaminases and synthetic function, reduced liver histopathology and reversed hepatobiliary fibrosis. The reversal of hepatobiliary fibrosis was likely due to the reduced activation state of hepatic stellate cells, decreased collagen deposition, and enhanced extracellular matrix remodeling *via* the up-regulation of MMP-13 and down-regulation of TIMP-1.

## CONCLUSION

Transplanted hUC-MSCs could differentiate into functional hepatocytes that improved both the biochemical and histopathologic changes in a CCl<sub>4</sub>-induced rat liver fibrosis model. hUC-MSCs may offer therapeutic opportunities for treating hepatobiliary diseases, including cirrhosis.

**Key words:** Liver fibrosis/cirrhosis; Mesenchymal stem cells; Collagen metabolism; Hepatocyte; Differentiation

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Transplanted human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) could differentiate into hepatocytes *in vivo*, thereby reducing the activation state of hepatic stellate cells, decreasing collagen deposition, and enhancing extracellular matrix remodeling in liver cirrhosis. hUC-MSCs play an important role in treating liver fibrosis and cirrhosis.

Zhang GZ, Sun HC, Zheng LB, Guo JB, Zhang XL. *In vivo* hepatic differentiation potential of human umbilical cord-derived mesenchymal stem cells: Therapeutic effect on liver fibrosis/cirrhosis. *World J Gastroenterol* 2017; 23(46): 8152-8168 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i46/8152.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i46.8152>

## INTRODUCTION

Chronic liver inflammation is a major driving force for extracellular matrix (ECM) accumulation and can lead to liver cirrhosis with resultant complications such as portal hypertension and hepatocellular carcinoma<sup>[1,2]</sup>. The economic burden of cirrhosis is significant with the cost for treatment in 2008 ranging from \$14 million to \$2 billion in the United States, depending on the disease etiology<sup>[3]</sup>. This burden is expected to rise over the next 20 years. Given that cirrhosis is a worldwide problem that is associated with substantial socioeconomic burden, effective therapeutic strategies would be impactful.

Liver transplantation is an effective method for treating end-stage liver disease, but donor scarcity and

immunological rejection limit its clinical application<sup>[4]</sup>. This has led to the search for alternative sources of hepatocytes, including cell-based therapy using mesenchymal stem cells (MSCs). MSCs are multipotent stromal cells that can differentiate into a variety of cell types. MSCs, including bone marrow-derived MSCs (BM-MSCs), have been demonstrated to reduce the generation of ECM and collagen deposition, thereby ameliorating liver fibrosis and cirrhosis<sup>[5,6]</sup>. In addition, BM-MSCs can differentiate into functional hepatocytes to repair damaged liver tissue, improving liver fibrosis and cirrhosis<sup>[7]</sup>.

Among various MSCs types, human umbilical cord-derived MSCs (hUC-MSCs) may be best as an alternative for hepatocyte transplantation, because of their ease of extraction, low risk of viral transmission, low immunogenicity and immunosuppressive effects. To better understand the mechanism and therapeutic potential of hUC-MSCs, we developed a CCl<sub>4</sub>-induced rat liver fibrosis/cirrhosis model. We described the dynamic differentiation process of hUC-MSCs into functional hepatocytes *in vivo* and showed that transplanted hUC-MSCs can improve biochemical and histological abnormalities in this model. Our data suggest that hUC-MSCs may be an attractive, alternative therapeutic for treating liver disease, including cirrhosis.

## MATERIALS AND METHODS

### MSC isolation and culture

The umbilical cord was cut into 1-mm<sup>3</sup> pieces and filtered through a 1.5-mm mesh. Filtered umbilical cord pieces were seeded in DMEM/F12 complete medium. Fresh medium was replaced every 3 to 4 d, and non-adherent cells were discarded. When the observed cells reached 80% confluency, hUC-MSCs were separated by trypsin digestion, cultured, and identified by Alliantcells Bioscience Co., Ltd.

### Animal models

One hundred and twenty adult male Wistar rats, weighing 350-450 g, were obtained from the Experimental Animal Center of Hebei Medical University. The research was conducted in accordance with the internationally accepted principles for laboratory animal use and care, as found in the US guidelines (NIH publication #85-23, revised in 1985). The experiment was performed in compliance with the national ethical guidelines for the care and use of laboratory animals (Certificate No. 911102).

Rat models of liver fibrosis and cirrhosis were established by hypodermic injection of CCl<sub>4</sub> mixed with olive oil at a concentration of 40% (2 mL/kg) every Monday and Thursday. Rats injected with saline served as a control group. In the fibrosis group, after the sixth injection of CCl<sub>4</sub>, 5 × 10<sup>6</sup> hUC-MSCs were injected into the rats *via* the tail vein. Rats continued to be treated

with CCl<sub>4</sub>. After 1, 2, or 4 wk of hUC-MSCs infusion, rats were sacrificed to assess the related index of liver fibrosis. In the cirrhosis group, rats were treated with CCl<sub>4</sub> for up to 6 wk, and  $5 \times 10^6$  hUC-MSCs were injected into the rats *via* the tail vein. Rats continued to be treated with CCl<sub>4</sub>. After 2, 4, or 8 wk, rats were sacrificed to determine the related indicators. In the control group, the same volumes of saline were injected into the rats *via* the tail vein.

### **Serum parameter determination**

Alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), total bilirubin (TBIL) and direct bilirubin (DBIL) were evaluated in the samples of serum obtained at the end of the experiment. All tests were completed using the BECKMAN COULTER CX9 automatic biochemical analyzer.

### **Histopathology**

Liver specimens were fixed for 12-24 h in 4% phosphate-buffered paraformaldehyde (Huarui Scientific and Technological Co.) and then embedded in paraffin for light microscopy examination. Tissue sections (3  $\mu$ m thick) were stained with hematoxylin and eosin (H&E) for morphological evaluation and Masson trichrome (MT) to assess the degree of fibrosis.

### **Immunofluorescence**

Immunofluorescent studies were performed on 3- $\mu$ m paraffin-embedded liver sections. Briefly, the sections were fixed with 4% phosphate-buffered paraformaldehyde and washed with 0.1% TritonX-100 TBS (TBSTx). Five percent bovine serum albumin (BSA) in TBSTx was used as a sealed liquid and then the specimens were incubated overnight at 4 °C with mouse monoclonal anti-human specific albumin (ALB) antibody (1:100; BETHYL) and mouse monoclonal anti-human specific  $\alpha$ -fetoprotein (AFP) antibody (1:100; Thermo Scientific, Inc., United States). After the sections were washed, the Cy3-labeled goat anti-mouse IgG secondary antibody or FITC-labeled goat anti-rabbit (1:400 dilution) (Beyotime Institute of Biotechnology, Shanghai, China) was added and the sections were incubated at 37 °C for 1 h. DAPI (4', 6-diamidino-2-phenylindole) was used for nuclear staining. The negative control samples were processed under the same conditions, except that 5% BSA in TBSTx was used in place of the primary antibody. The ALB and AFP positive expression levels were measured using a Motic Med 6.0 digital video image analysis system (Motic China Group Co., Ltd., Xiamen, China) and expressed as optical density values.

### **Immunohistochemistry**

Immunohistochemistry studies were performed on 3- $\mu$ m paraffin-embedded liver sections. The sections were fixed with 4% phosphate-buffered

paraformaldehyde and washed with PBS. Five percent BSA in TBSTx was used as a sealed liquid, and the specimens were then incubated overnight at 4 °C with the primary antibody mouse monoclonal anti-human specific CK18 antibody (1:200; Thermo Scientific, Inc.), mouse monoclonal anti-human specific CK19 antibody (1:200; Thermo Scientific, Inc.), mouse monoclonal anti-human specific vimentin antibody (1:200; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, United States), mouse monoclonal anti-human specific E-cadherin antibody (1:200; Santa Cruz Biotechnology, Inc.), mouse monoclonal anti-human specific  $\alpha$ -catenin antibody (1:200; Santa Cruz Biotechnology, Inc.), rabbit monoclonal anti- $\alpha$ -SMA antibody (1:200; Santa Cruz Biotechnology, Inc.), goat polyclonal anti-collagen I antibody (1:100; Santa Cruz Biotechnology, Inc.), mouse polyclonal anti-collagen III antibody (1:200; Santa Cruz Biotechnology, Inc.), rabbit polyclonal anti-MMP-13 antibody (1:200; Boaosen, Beijing, China), and rabbit polyclonal anti-TIMP-1 antibody (1:200; Santa Cruz Biotechnology, Inc.). After incubation with peroxidase-conjugated secondary antibody, signals were visualized with a diaminobenzidine peroxidase substrate kit (Vector Laboratories). The negative control samples were processed under the same conditions, except that 5% BSA in TBSTx was used in place of the primary antibody. The expression levels were measured using a Motic Med 6.0 digital video image analysis system (Motic China Group Co., Ltd.) and expressed as optical density values.


### **Western blot analysis**

Primary antibodies included mouse anti-CK18, CK19, ALB, and AFP monoclonal antibodies (1:500); mouse anti-vimentin, E-cadherin, and  $\alpha$ -catenin antibodies (1:200); goat anti-collagen I polyclonal antibody (1:100); mouse anti-collagen III polyclonal antibody (1:500); rabbit anti-MMP-13 and TIMP-1 polyclonal antibody (1:200) and rabbit anti- $\beta$ -actin monoclonal antibody (1:200). Western blot was performed as previously described<sup>[8]</sup>.

### **Real-time fluorescent quantitative PCR**

Total RNA was extracted with TRIzol reagent (Invitrogen, United States) according to the manufacturer's instructions. cDNA was generated using 2  $\mu$ g of total RNA as described<sup>[9]</sup>.

Primer Express 5.0 was used to design the following primers: ALB forward primer, 5'-GCT TGA ATG TGC TGA TGA CAG G-3' and reverse primer, 5'-TGG GAT TTT TCC AAC AGA GGT T-3'; AFP forward primer, 5'-AAG TGA AGA GGG AAG ACA TAA C-3' and reverse primer, 5'-AGA AGA ATT GTA GGT GCA TAC A-3'; CK18 forward primer, 5'-TAA TCT TGG TGA TGC CTT GGA C-3' and reverse primer, 5'-CCT CAG AAC TTT GGT GTC ATT G-3'; CK19 forward primer, 5'-GCC ACT ACT ACA CGA CCA TCC A-3' and reverse primer, 5'-AGA GCC



**Figure 1 Morphology of umbilical cord-derived mesenchymal stem cells and immunophenotype analysis using FACS.** A: The morphology of umbilical cord-derived mesenchymal stem cells (UC-MSCs) ( $\times 100$ ); B: Immunophenotype analysis using FACS. The 3rd passage hUC-MSCs are shown, and the adherent cells displayed a fibroblastic morphology. Immunophenotype analysis using FACS showed that hUC-MSCs were positive for the human MSC-specific markers CD90, CD105 and CD73 but were negative for CD34, CD19, CD11b, HLA-DR and CD45.

TGT TCC GTC TCA AAC T-3'; vimentin forward primer, 5'-ATG TTG ACA ATG CGT CTC TGG CTC CA-3' and

reverse primer, 5'-ATT TCC TCT TCG TGG AGT TTC T-3'; N-cadherin forward primer, 5'-CAG CCT CCA ACT GGT

ATC TTC A-3' and reverse primer, 5'-ATC TAC TGC ATG TGC CC TCA AA-3'; E-cadherin forward primer, 5'-CCA GGA GGT CTT TAA GGG GTC T-3' and reverse primer, 5'-GCT GAGG ATG GTG TAA GCG ATG-3';  $\alpha$ -catenin forward primer, 5'-GCA AAG AAT GGA AAT GAG AAA G-3' and reverse primer, 5'-AAT AAC CTG AGG ACA GAG GGC T-3'; collagen I forward primer, 5'-GTG CGA TGG GGT GCT ATG-3' and reverse primer, 5'-TCT GCG TCT GGT GAT ACA TAT TC-3'; collagen III forward primer, 5'-ACC TGC TCC TGT CAT TCC-3' and reverse primer, 5'- CCT CCG ACT CCA GAC TTG-3'; MMP-13 forward primer, 5'-CCA CCT TCT TGT TGA GTT G-3' and reverse primer, 5'-AAG AGT CAC AGG ATG GTA GTA TG-3'; TIMP-1 forward primer, 5'-CGC TGG TAT AAG GTG GTC TC-3' and reverse primer, 5'-CGC TGG TAT AAG GTG GTC TC-3'; and GAPDH forward primer, 5'-GGC AAG TTC AAC GGC ACA G-3' and reverse primer, 5'-CGC CAG TAG ACT CCA CGA CAT -3'. Real-time fluorescent quantitative PCR was performed on an ABI Prism 7700 real-time fluorescent quantitative PCR thermal cycler (Applied Biosystems, Foster City, CA, United States), and the expression of the above genes was normalized to that of GAPDH.

### Statistical analysis

Data are presented as the mean  $\pm$  SD and analyzed using SPSS18.0 software. The performed statistical analyses included one-way ANOVA, the LSD test and Pearson's correlation analysis.  $P < 0.05$  was considered statistically significant.

## RESULTS

### Characterization of hUC-MSCs *in vitro* and *in vivo*

We isolated hUC-MSCs that exhibited fibroblast-like morphology from the umbilical cord (Figure 1A). Flow cytometry showed that hUC-MSCs expressed high levels of MSCs-specific markers CD90, CD105 and CD73 but no or low levels of CD34, CD19, CD11b, HLA-DR and CD45 (Figure 1B). We next transplanted hUC-MSCs into rats and assessed their potential to differentiate into hepatocytes. We detected ALB, AFP, CK18 and CK19 from human origin, but the rat-derived ALB, AFP, CK18 and CK19 were not detected. Therefore, the differentiated hepatocytes of rats had no effect on the results. Prior to transplantation, there was no positive expression of human ALB, AFP, CK18 or CK19. After transplantation, we detected the expression of the above markers.

Immunofluorescence and immunohistochemistry showed that compared to the saline/CCl<sub>4</sub> groups, the positive expression of the above markers showed different patterns in the MSCs/CCl<sub>4</sub> fibrotic and cirrhotic groups. The expression of ALB, AFP, CK18 and CK19 was weakly positive and faint in spots at 1 or 2 wk, respectively, in the MSCs/CCl<sub>4</sub> fibrotic and cirrhotic groups. However, at 2, 4, or 8 wk after hUC-MSC infusion, with an extension of the transplantation time,


the positive expression of ALB, AFP, CK18 and CK19 was gradually increased, in addition to the decreased expression of the AFP and CK19 in the MSCs/CCl<sub>4</sub> cirrhotic group at 8 wk after hUC-MSC infusion.

The mRNA levels of ALB and CK18 were not significantly different between 2 wk and 1 wk in the MSCs/CCl<sub>4</sub> fibrotic groups, while the expression of ALB and CK18 mRNAs was significantly increased at 4 wk compared to 2 wk ( $P < 0.01$ ). With the extension of the transplantation time, the expression levels of AFP and CK19 mRNAs were significantly elevated ( $P < 0.01$ ). In the cirrhotic MSCs/CCl<sub>4</sub> groups, the expression levels of AFP and CK19 mRNAs were significantly elevated at 4 wks compared to 2 wk ( $P < 0.01$ ). However, the expression levels of AFP and CK19 mRNAs were significantly decreased at 8 wk compared to 4 wk ( $P < 0.01$ ); as the time of hUC-MSC transplantation was extended, the expression levels of ALB and hCK18 increased, and the relative protein quantitation was consistent with the above results (Figure 2).


### *hUC-MSCs differentiate into hepatocyte-like cells through the mesenchymal-to-epithelial transition in vivo*

Next, we analyzed the levels of human vimentin (a mesenchymal marker) and human E-cadherin and  $\alpha$ -catenin (epithelial markers) by immunohistochemistry, Western blot and real-time PCR. To determine whether hUC-MSCs experienced the mesenchymal-to-epithelial transition (MET) during hepatocyte differentiation *in vivo*, the expression levels of vimentin, E-cadherin and  $\alpha$ -catenin were detected. After 1 or 2 wk of hUC-MSC transplantation, in the fibrotic and cirrhotic MSCs/CCl<sub>4</sub> groups, many positive cells for vimentin were expressed in the portal vein and portal area. As the time of hUC-MSC transplantation extended, the expression of vimentin was significantly decreased in both the fibrotic and cirrhotic MSCs/CCl<sub>4</sub> groups. At 8 wk after hUC-MSC transplantation, a low level of vimentin was expressed. There was no expression before hUC-MSC transplantation. The relative expression levels of protein and mRNA were consistent with the above results ( $P < 0.01$ ).


In the fibrotic MSCs/CCl<sub>4</sub> groups, at 1 wk after hUC-MSC transplantation, low levels of E-cadherin and  $\alpha$ -catenin expression were detected by immunohistochemistry, which gradually increased with the extension of hUC-MSC transplantation. In the cirrhotic MSCs/CCl<sub>4</sub> groups, at 2 wk after hUC-MSC transplantation, low E-cadherin and  $\alpha$ -catenin levels were seen. The E-cadherin and  $\alpha$ -catenin expressions levels were significantly increased at 4 wk after hUC-MSCs transplantation compared to 2 wk in the fibrotic and cirrhotic MSCs/CCl<sub>4</sub> groups. By contrast, the levels of the above indicators decreased significantly at 8 wk compared to 4 wk after hUC-MSC transplantation. The relative protein and mRNA expression levels were



**Figure 2** Expression of human hepatic markers in rat liver tissues. A, C, and E: Immunohistochemical, Western blot, and real-time PCR analysis of human albumin (ALB), α-fetoprotein (AFP), CK18, and CK19 in rat fibrotic livers at 0, 1, 2, and 4 wk after human umbilical cord-derived mesenchymal stem cell (hUC-MSC) transplantation, respectively; B, D, and F: Immunohistochemical, Western blot, and real-time PCR analysis of human ALB, AFP, CK18, or CK19 in rat cirrhotic livers at 0, 2, 4, and 8 wk after hUC-MSC transplantation, respectively, <sup>a</sup>*P* < 0.05; <sup>b</sup>*P* < 0.01.



**Figure 3** Expression of human vimentin, a mesenchymal marker, and human E-cadherin and  $\alpha$ -catenin, epithelial markers, in rat liver tissues. A, C, and E: Immunohistochemical, Western blot, and real-time PCR analysis of human vimentin, E-cadherin and  $\alpha$ -catenin in rat fibrotic livers at 0, 1, 2, and 4 wk after human umbilical cord-derived mesenchymal stem cell (hUC-MSC) transplantation, respectively; B, D, and F: Immunohistochemical, Western blot, and real-time PCR analysis of human vimentin, E-cadherin and  $\alpha$ -catenin in rat cirrhotic livers at 0, 2, 4, and 8 wk after hUC-MSC transplantation, respectively, <sup>b</sup>*P* < 0.01.



**Figure 4** Representative photographs of the fresh livers, hematoxylin and eosin staining (H&E staining), Masson's trichrome staining (MT staining) and sirius red staining in rat fibrotic or cirrhotic hepatic tissues. Liver sections were stained with hematoxylin and eosin (H&E,  $\times 400$ ), Masson's trichrome (MT,  $\times 100$ ) and Sirius red ( $\times 100$ ) or representative photographs of the fresh livers without fixation were used to evaluate histopathological changes for liver tissues in control conditions; with CCl<sub>4</sub> for 3 wk; or with 1, 2, and 4 wk in fibrotic rat tissues; with CCl<sub>4</sub> for 6 wk; or with 2, 4, and 8 wk in cirrhotic rat tissues after human umbilical cord-derived mesenchymal stem cell (hUC-MSC) or saline injection into rats.

**Table 1** Impact of mesenchymal stem cells on liver function indexes in each group ( $n = 10$ , mean  $\pm$  SD)


Group		ALT(U/L)	AST(U/L)	ALB(g/L)	TBIL ( $\mu$ mol/L)	DBIL ( $\mu$ mol/L)
Liver fibrosis groups	Saline/CCl <sub>4</sub> 1 wk	141.00 $\pm$ 16.33	150.76 $\pm$ 15.13	29.99 $\pm$ 1.53	0.97 $\pm$ 0.15	0.70 $\pm$ 0.02
	MSCs/CCl <sub>4</sub> 1 wk	130.32 $\pm$ 15.35	142.32 $\pm$ 14.24	32.17 $\pm$ 2.25	0.93 $\pm$ 0.08	0.60 $\pm$ 0.04
	Saline/CCl <sub>4</sub> 2 wk	152.35 $\pm$ 14.56	172.22 $\pm$ 19.34	24.54 $\pm$ 1.21	1.51 $\pm$ 0.21	0.90 $\pm$ 0.07
	MSCs/CCl <sub>4</sub> 2 wk	132.88 $\pm$ 13.23 <sup>a</sup>	146.23 $\pm$ 13.23 <sup>a</sup>	26.60 $\pm$ 2.34	1.33 $\pm$ 0.25	0.70 $\pm$ 0.05
	Saline/CCl <sub>4</sub> 4 wk	239.24 $\pm$ 26.32	262.34 $\pm$ 28.12	28.12 $\pm$ 2.13	2.10 $\pm$ 0.23	1.10 $\pm$ 0.17
	MSCs/CCl <sub>4</sub> 4 wk	192.32 $\pm$ 21.24 <sup>b</sup>	204.52 $\pm$ 23.24 <sup>b</sup>	21.12 $\pm$ 1.94 <sup>b</sup>	1.57 $\pm$ 0.15 <sup>b</sup>	0.50 $\pm$ 0.03 <sup>b</sup>
Liver cirrhosis groups	Saline/CCl <sub>4</sub> 2 wk	334.36 $\pm$ 37.48	375.24 $\pm$ 41.26	26.55 $\pm$ 1.51	2.27 $\pm$ 0.15	1.32 $\pm$ 0.12
	MSCs/CCl <sub>4</sub> 2 wk	204.31 $\pm$ 22.52 <sup>c</sup>	289.13 $\pm$ 32.22 <sup>c</sup>	19.62 $\pm$ 1.54	1.90 $\pm$ 0.14 <sup>c</sup>	0.80 $\pm$ 0.09 <sup>c</sup>
	Saline/CCl <sub>4</sub> 4 wk	353.35 $\pm$ 38.76	406.24 $\pm$ 44.31	22.69 $\pm$ 2.72	3.34 $\pm$ 0.76	2.07 $\pm$ 0.15
	MSCs/CCl <sub>4</sub> 4 wk	214.11 $\pm$ 23.24 <sup>d</sup>	292.24 $\pm$ 32.32 <sup>d</sup>	20.36 $\pm$ 1.53 <sup>d</sup>	2.06 $\pm$ 0.14 <sup>d</sup>	1.10 $\pm$ 0.13 <sup>d</sup>
	Saline/CCl <sub>4</sub> 8 wk	391.22 $\pm$ 43.57	418.63 $\pm$ 45.71	19.31 $\pm$ 1.52	4.82 $\pm$ 0.52	3.74 $\pm$ 0.25
	MSCs/CCl <sub>4</sub> 8 wk	247.31 $\pm$ 27.36 <sup>e</sup>	307.22 $\pm$ 34.36 <sup>e</sup>	23.70 $\pm$ 7.72 <sup>e</sup>	3.32 $\pm$ 0.31 <sup>e</sup>	2.13 $\pm$ 0.15 <sup>e</sup>

<sup>a</sup> $P < 0.05$  vs Saline/CCl<sub>4</sub> 2 wk, <sup>b</sup> $P < 0.05$  vs Saline/CCl<sub>4</sub> 4 wk (in the liver fibrosis groups); <sup>c</sup> $P < 0.05$  vs Saline/CCl<sub>4</sub> 2 wk, <sup>d</sup> $P < 0.01$  vs Saline/CCl<sub>4</sub> 4 wk, and <sup>e</sup> $P < 0.01$  vs Saline/CCl<sub>4</sub> 8 wk (in the liver cirrhosis groups). ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALB: Albumin; TBIL: Total bilirubin; DBIL: Direct bilirubin.

**Table 2 Inflammation scores in each group (n = 10, mean ± SD)**

	Liver fibrosis groups			Liver cirrhosis groups		
	1 wk	2 wk	4 wk	2 wk	4 wk	8 wk
Saline/CCl <sub>4</sub>	1.63 ± 0.05	1.95 ± 0.06	2.67 ± 0.08	3.09 ± 0.07	3.61 ± 0.09	4.12 ± 0.11
MSCs/CCl <sub>4</sub>	1.25 ± 0.04	1.45 ± 0.05 <sup>a</sup>	1.75 ± 0.07 <sup>b</sup>	2.15 ± 0.06 <sup>c</sup>	2.28 ± 0.07 <sup>d</sup>	3.06 ± 0.08 <sup>d</sup>

<sup>a</sup>P < 0.05 vs Saline/CCl<sub>4</sub> 2 wk, <sup>b</sup>P < 0.05 vs Saline/CCl<sub>4</sub> 4 wk (in the liver fibrosis groups); <sup>c</sup>P < 0.05 vs Saline/CCl<sub>4</sub> 2 wk, <sup>d</sup>P < 0.01 vs Saline/CCl<sub>4</sub> 4 wk, (in the liver cirrhosis groups).



**Figure 5 Immunohistochemical staining for  $\alpha$ -smooth muscle actin in hepatic fibrosis and cirrhosis groups (× 400).** A: Immunohistochemical staining for  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA) in hepatic fibrosis groups; B: Immunohistochemical staining for  $\alpha$ -SMA in hepatic cirrhosis groups. In normal rat liver,  $\alpha$ -SMA was occasionally detected in vascular smooth muscle cells, and the expression level was low, revealing few activated hepatic stellate cells (HSCs). After CCl<sub>4</sub> administration, the  $\alpha$ -SMA spread to the portal area, showing more activated HSCs. The expression of  $\alpha$ -SMA in liver tissues increased significantly in the saline infusion group compared with the normal group. Compared with the saline infusion groups, they significantly decreased in the MSC transplantation groups.

consistent with these results ( $P < 0.01$ ; Figure 3).

***hUC-MSCs improve the biochemical indexes in the CCl<sub>4</sub>-induced hepatic injury model***

CCl<sub>4</sub>-induced hepatic injury in rats has been used as a model system to study liver damage and fibrosis, and we used this model to assess the therapeutic effect of hUC-MSCs. The hUC-MSCs were transplanted into a CCl<sub>4</sub>-induced liver fibrotic/cirrhotic rat model, and we observed a significant reduction in the serum levels of ALT and AST at 2 and 4 wk in the fibrotic MSCs/CCl<sub>4</sub>

groups and at 2, 4, and 8 wk in the cirrhotic MSCs/CCl<sub>4</sub> groups ( $P < 0.05$ ). In addition, the serum level of ALB was gradually reduced with further CCl<sub>4</sub> induction in the fibrotic and cirrhotic saline/CCl<sub>4</sub> groups, whereas after the transplantation of hUC-MSCs, the serum levels of ALB were markedly increased at 4 wk in the fibrotic MSCs/CCl<sub>4</sub> groups and at 4 and 8 wk in the cirrhotic MSCs/CCl<sub>4</sub> groups ( $P < 0.05$ ). Compared with the saline/CCl<sub>4</sub> groups, the serum levels of TBIL and DBIL greatly dropped at 4 wk in the fibrotic MSCs/CCl<sub>4</sub> groups and at 2, 4, and 8 wk in the cirrhotic MSCs/CCl<sub>4</sub>

groups ( $P < 0.05$ ; Table 1). The inflammation score in rat liver fibrosis and cirrhosis induced by CCl<sub>4</sub> in each group are listed in Table 2.

### ***hUC-MSCs reverse the CCl<sub>4</sub>-induced liver histopathological changes***

Transplantation of hUC-MSCs improved the gross liver morphology by reducing the surface coarseness, reducing the liver turgor, and improving the liver perfusion (Figure 4, right panels).

Histologic examination of the CCl<sub>4</sub>-treated liver revealed swelling of the hepatocytes, fatty degeneration, necrosis and regeneration, particularly with continued CCl<sub>4</sub> administration (Figure 4). These alterations were reduced after the infusion of hUC-MSCs.

To determine the extent of the collagen deposition, MT and Sirius red staining were performed. By 3 wk after CCl<sub>4</sub> injection, liver fibrosis was observed (Figure 4), as evidenced by fiber extension, large fibrous septa formation, pseudo lobe separation and collagen accumulation in the periportal region. These alterations were remarkably reduced after infusion of hUC-MSCs (Figure 4). Together, our data show that transplanted hUC-MSCs can reverse established liver histopathology induced by CCl<sub>4</sub>.

### ***hUC-MSCs inhibit the activation of HSCs and reduce collagen deposition***

To study the possible impact of hUC-MSCs on HSC activation and collagen deposition, immunohistochemistry was performed to detect the  $\alpha$ -SMA and collagen I and III expression. With the progression of liver fibrosis, positive  $\alpha$ -SMA, collagen I and collagen III cells in the rat liver tissue gradually increased, mainly in the portal area, fibrous septa and hyperplasia of bile duct cells. Compared with the saline/CCl<sub>4</sub> group, the positive expression of  $\alpha$ -SMA and collagen I and III in the MSCs/CCl<sub>4</sub> group was reduced, although they gradually increased as the time of transplantation extended. In addition, hUC-MSCs significantly reduced the protein and mRNA expression of collagen I and III in the fibrotic and cirrhotic groups ( $P < 0.05$ ), except in the first week after hUC-MSC transplantation in these groups (Figures 5 and 6).

### ***hUC-MSCs reduce the collagen deposition by up-regulating MMP-13 expression and down-regulating TIMP-1 expression***

To detect the mechanism by which hUC-MSCs reduce collagen deposition, immunohistochemical analysis for MMP-13 and TIMP-1, which are mainly expressed in the cells of portal area and the central vein area, was performed in the liver tissues of fibrotic and cirrhotic rats. With the extension of the CCl<sub>4</sub> induction time, MMP-13 and TIMP-1 gradually increased in both the saline/CCl<sub>4</sub> groups and MSCs/CCl<sub>4</sub> groups. After the same CCl<sub>4</sub> injection, the MMP-13 in the MSCs/CCl<sub>4</sub> groups significantly increased compared with the


saline/CCl<sub>4</sub> groups. However, in the MSCs/CCl<sub>4</sub> groups, the expression of TIMP-1 decreased compared with the saline/CCl<sub>4</sub> groups. Western blot and real-time PCR were further applied, which showed that hUC-MSCs significantly lowered the collagen deposition by increasing MMP-13 expression ( $P < 0.05$ ) and decreasing TIMP-1 ( $P < 0.05$ ) expression, except in the first week after the transplantation of hUC-MSCs in the fibrotic MSCs/CCl<sub>4</sub> groups (Figure 7).

## **DISCUSSION**


At present, liver cirrhosis and other chronic liver diseases seriously affect human health, and liver transplantation is an effective treatment. However, many of its side effects limit its clinical applications. Stem cell-based therapy is of potential value in tissue and organ replacement and regeneration. Among various types of MSCs, hUC-MSCs are optimal with many advantages, such as easy extraction, low risk of viral transmission, low immunogenicity and immunosuppressive effects<sup>[10,11]</sup>.

Hepatocytes undergo damage in case of liver cirrhosis. In addition, under the given conditions, MSCs can differentiate into bone, nerve cells, hepatocytes and many other cell types<sup>[12-16]</sup>. Human MSCs differentiated into hepatocyte-like cells *in vitro*<sup>[17]</sup>. Can MSCs differentiate into hepatocyte-like cells to replace damaged hepatocytes that play a role *in vivo*? Piryaei *et al.*<sup>[18]</sup> found that BM-MSCs could differentiate into hepatocyte-like cells in the liver fibrotic mice *in vivo*. Another study also confirmed that MSCs infused into the CCl<sub>4</sub>-induced liver fibrotic rats could differentiate into hepatocyte-like cells<sup>[19]</sup>. Human MSCs labelled with CM-Di I well integrated into the injured liver tissue in CCl<sub>4</sub>-induced cirrhotic rats<sup>[20]</sup>. Our study showed that the expression of human ALB, AFP, CK18 and CK19 was detected in liver tissue of the fibrotic and cirrhotic rats after hUC-MSC transplantation. Human ALB and CK18 were weakly detected after 1 wk of hUC-MSC transplantation, and they were increased in a time-dependent manner. Interestingly, the human AFP and CK19 expression levels first increased and then decreased with the extension of the transplantation time. These results suggest that transplanted hUC-MSCs could migrate into the injured liver in CCl<sub>4</sub>-induced fibrosis and cirrhosis, where they could differentiate into hepatocyte-like cells. Few hUC-MSCs differentiated into hepatocyte-like cells within 1 wk after hUC-MSC transplantation. hUC-MSCs first differentiated into immature hepatocytes and later became mature, which was a dynamic differentiation process.


Yamamoto *et al.*<sup>[21]</sup> induced adipose tissue-derived MSCs (AT-MSCs) to differentiate into AT-MSC-derived hepatocytes (AT-MSC-Hepas) *in vitro*. AT-MSC-Hepas had epithelial cell-like morphology. However, undifferentiated AT-MSCs had a fibroblast-like shape,





**C**




**D**



**E**





**Figure 6 Changes of collagen I and III in the liver fibrosis and cirrhosis groups.** A, C, and E: Immunohistochemical, Western blot, and real-time PCR analysis of collagen I and III in fibrotic livers, respectively, in normal rats, rats at 3 wk after CCl<sub>4</sub> treatment, and rats at 1, 2, or 4 wk after human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) transplantation; B, D, and F: Immunohistochemical, Western blot, and real-time PCR analysis of collagen I and III in cirrhotic livers, respectively, in normal rats; rats at 6 wk after CCl<sub>4</sub> treatment; and rats at 2, 4, or 8 wk after hUC-MSC transplantation.

indicating that during hepatic differentiation, the cell morphology changed markedly from fibroblast cell-like to epithelial cell-like. Meanwhile, microarray analysis showed that Twist and Snail, which induced the epithelial-to-mesenchymal transition, were down-regulated in the hepatic differentiation process. In addition, the expression levels of E-cadherin and  $\alpha$ -catenin, genes expressed in epithelial cells, were up-regulated in MSC-derived hepatocytes. In contrast, the expression of vimentin and N-cadherin, genes expressed in interstitial cells, was down-regulated after differentiation. Tsai *et al.*<sup>[22]</sup> reported that the phosphorylation of a factor of liver mesenchymal epithelial conversion was up-regulated in rats with HMSC transplantation. In summary, these data support the hypothesis that MET occurs during the hepatic differentiation of MSCs.



We previously confirmed that hUC-MSCs could differentiate into functional hepatocytes in liver fibrosis and cirrhosis in rats. Do hUC-MSCs undergo the MET during this differentiation? A recent study speculated that MET might be one of the mechanisms for lung hMSCs to treat chronic lung diseases<sup>[23]</sup>. Our study confirmed that vimentin and N-cadherin expression was gradually reduced in both fibrotic and cirrhotic rats with the extension of hUC-MSC transplantation. However, E-cadherin and  $\alpha$ -catenin expression first increased and then decreased, indicating that hUC-MSCs did not directly differentiate into functional hepatocytes; instead, they first differentiated into epithelial cell-like cells and then differentiated into hepatocyte-like cells. During this differentiation process, epithelial cell-like cells were in the intermediate stage.

BM-MSCs and hepatocytes transplanted into CCl<sub>4</sub>-



induced liver fibrotic rats were evaluated after co-culture for 14 d; then, after 1, 3, or 4 wk, rats were sacrificed. The results showed that hepatic fibrosis was markedly improved, indicating the therapeutic effect of BM-MSCs on liver fibrosis<sup>[24]</sup>. In liver cirrhosis, activated HSCs are the main source of the ECM, with collagen I and III as the main ingredients. A recent study has demonstrated that human MSCs implanted into CCl<sub>4</sub>-induced liver cirrhotic rats inhibited the expression of collagen I and  $\alpha$ -SMA, improving liver cirrhosis<sup>[25]</sup>. Our results showed that hUC-MSC infusion significantly reduced the deposition of collagen I and III, except in the first week after hUC-MSCs transplantation, indicating that hUC-MSCs had a therapeutic effect at a late stage rather than immediately at onset.

Under normal conditions, the collagenase mainly maintains collagen balance. MMP-13, a rodent interstitial metal collagenase, plays a major role in the balance of the contents of collagen I and III, which can be inhibited by TIMP-1. How do the MSCs participate in collagen metabolism? In this study, hUC-MSC transplantation degraded collagen deposition and clearly improved liver fibrosis with the up-regulation of MMP-13 expression and reduction of TIMP-1 expression. As indicated by immunohistochemical staining, Western blot and real-time PCR, MSCs reduced the collagen deposition by up-regulating MMP expression and down-regulating TIMP expression.



These data support that hUC-MSCs have the potential for hepatic differentiation *in vivo* and hUC-MSC transplantation could exert a protective effect against liver fibrosis/cirrhosis, suggesting that these cells may provide a new approach for cell therapy in liver diseases. The exact mechanisms by which hUC-MSCs repair liver injury and undergo hepatic di-





**C**




**D**



**E**





**Figure 7** Expression of MMP-13 and TIMP-1 in the liver fibrosis or cirrhosis groups. A, C, and E: Immunohistochemical, Western blot, and real-time PCR analysis of MMP-13 and TIMP-1 in rat fibrotic livers, respectively, in normal rats; rats at 3 wk after CCl<sub>4</sub> treatment; and rats at 1, 2, or 4 wk after human umbilical cord-derived mesenchymal stem cell (hUC-MSC) transplantation; B, D, and F: Immunohistochemical, Western blot, and real-time PCR analysis of MMP-13 and TIMP-1 in rat cirrhotic livers, respectively, in normal rats; rats at 6 wk after CCl<sub>4</sub> treatment; and rats at 2, 4, or 8 wk after hUC-MSC transplantation.

fferentiation remain to be elucidated in future studies.

## COMMENTS

### Background

Chronic liver inflammation is a major driving force for extracellular matrix accumulation, leading to liver cirrhosis with complications. Liver transplantation is an effective method for treating end-stage liver disease, but donor scarcity and immunological rejection limit its clinical application. This has led to the search for alternative sources of hepatocytes, including cell-based therapy using mesenchymal stem cells (MSCs). MSCs have been demonstrated to improve liver disease.

### Research frontiers

Among the various MSCs types, human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) may be optimal as an alternative for hepatocyte transplantation, because of ease of extraction, low risk of viral transmission, low immunogenicity and immunosuppressive effects. The authors used a CCl<sub>4</sub>-induced rat liver fibrosis/cirrhosis model to better understand the mechanism and therapeutic potential of hUC-MSCs.

### Innovations and breakthroughs

This is the first study to evaluate the *in vivo* hepatic differentiation potential of human umbilical cord-derived MSCs and their therapeutic effect on liver fibrosis.

### Applications

Transplanted hUC-MSCs could differentiate into functional hepatocytes that improved both biochemical and histopathologic changes in a CCl<sub>4</sub>-induced rat liver fibrosis model. hUC-MSCs may offer therapeutic opportunities in the treatment of hepatobiliary diseases, including cirrhosis.

### Terminology

The mesenchymal-to-epithelial transition is a crucial physiologic event that converts motile mesenchymal cells to polarized epithelial cells, favoring the epithelial regeneration. hUC-MSCs differentiated into hepatocyte-like cells *via* the mesenchymal-to-epithelial transition *in vivo*.

### Peer-review

Good research on cord stem cells in the treatment of liver disease. Change all typos saying "collagen I and III TO collagen I and III".

## ACKNOWLEDGMENTS

We thank Alliancells Bioscience Co., Ltd. for providing hUC-MSCs and the ENT laboratory, The First Hospital of Hebei Medical University for providing laboratory equipment on immunofluorescence and real-time PCR.

## REFERENCES

- 1 **Afdhal NH**, Manning D. Diagnosis of liver fibrosis in 2008 and beyond. *Gastroenterol Clin Biol* 2008; **32**: 88-90 [PMID: 18973851 DOI: 10.1016/S0399-8320(08)73998-8]
- 2 **Mormone E**, Lu Y, Ge X, Fiel MI, Nieto N. Fibromodulin, an oxidative stress-sensitive proteoglycan, regulates the fibrogenic response to liver injury in mice. *Gastroenterology* 2012; **142**: 612-621.e5 [PMID: 22138190 DOI: 10.1053/j.gastro.2011.11.029]
- 3 **Neff GW**, Duncan CW, Schiff ER. The current economic burden of cirrhosis. *Gastroenterol Hepatol* (N Y) 2011; **7**: 661-671 [PMID: 22298959]
- 4 **Baertschiger RM**, Serre-Beinier V, Morel P, Bosco D, Peyrou M, Clément S, Sgroi A, Kaelin A, Buhler LH, Gonelle-Gispert C. Fibrogenic potential of human multipotent mesenchymal stromal cells in injured liver. *PLoS One* 2009; **4**: e6657 [PMID: 19684854 DOI: 10.1371/journal.pone.0006657]
- 5 **Oyagi S**, Hirose M, Kojima M, Okuyama M, Kawase M, Nakamura T, Ohgushi H, Yagi K. Therapeutic effect of transplanting HGF-treated bone marrow mesenchymal cells into CCl<sub>4</sub>-injured rats. *J Hepatol* 2006; **44**: 742-748 [PMID: 16469408 DOI: 10.1016/j.jhep.2005.10.026]
- 6 **Zhao DC**, Lei JX, Chen R, Yu WH, Zhang XM, Li SN, Xiang P. Bone marrow-derived mesenchymal stem cells protect against experimental liver fibrosis in rats. *World J Gastroenterol* 2005; **11**: 3431-3440 [PMID: 15948250 DOI: 10.3748/wjg.v11.i22.3431]
- 7 **Ju S**, Teng GJ, Lu H, Jin J, Zhang Y, Zhang A, Ni Y. *In vivo* differentiation of magnetically labeled mesenchymal stem cells into hepatocytes for cell therapy to repair damaged liver. *Invest Radiol* 2010; **45**: 625-633 [PMID: 20808237 DOI: 10.1097/RLI.0b013e3181ed55f4]
- 8 **Hao LS**, Zhang XL, An JY, Karlin J, Tian XP, Dun ZN, Xie SR, Chen S. PTEN expression is down-regulated in liver tissues of rats with hepatic fibrosis induced by biliary stenosis. *APMIS* 2009; **117**: 681-691 [PMID: 19703128 DOI: 10.1111/j.1600-0463.2009.02515.x]

- 9 **Zheng L**, Chen X, Guo J, Sun H, Liu L, Shih DQ, Zhang X. Differential expression of PTEN in hepatic tissue and hepatic stellate cells during rat liver fibrosis and its reversal. *Int J Mol Med* 2012; **30**: 1424-1430 [PMID: 23041795 DOI: 10.3892/ijmm.2012.1151]
- 10 **Chen MY**, Lie PC, Li ZL, Wei X. Endothelial differentiation of Wharton's jelly-derived mesenchymal stem cells in comparison with bone marrow-derived mesenchymal stem cells. *Exp Hematol* 2009; **37**: 629-640 [PMID: 19375653 DOI: 10.1016/j.exphem.2009.02.003]
- 11 **Zhao Q**, Ren H, Li X, Chen Z, Zhang X, Gong W, Liu Y, Pang T, Han ZC. Differentiation of human umbilical cord mesenchymal stromal cells into low immunogenic hepatocyte-like cells. *Cytotherapy* 2009; **11**: 414-426 [PMID: 19513901 DOI: 10.1080/14653240902849754]
- 12 **Gregory CA**, Prockop DJ, Spees JL. Non-hematopoietic bone marrow stem cells: molecular control of expansion and differentiation. *Exp Cell Res* 2005; **306**: 330-335 [PMID: 15925588 DOI: 10.1016/j.yexcr.2005.03.018]
- 13 **La Rocca G**, Anzalone R, Corrao S, Magno F, Loria T, Lo Iacono M, Di Stefano A, Giannuzzi P, Marasà L, Cappello F, Zummo G, Farina F. Isolation and characterization of Oct-4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers. *Histochem Cell Biol* 2009; **131**: 267-282 [PMID: 18836737 DOI: 10.1007/s00418-008-0519-3]
- 14 **Yang XF**, He X, He J, Zhang LH, Su XJ, Dong ZY, Xu YJ, Li Y, Li YL. High efficient isolation and systematic identification of human adipose-derived mesenchymal stem cells. *J Biomed Sci* 2011; **18**: 59 [PMID: 21854621 DOI: 10.1186/1423-0127-18-59]
- 15 **Thanabalasundaram G**, Arumalla N, Tailor HD, Khan WS. Regulation of differentiation of mesenchymal stem cells into musculoskeletal cells. *Curr Stem Cell Res Ther* 2012; **7**: 95-102 [PMID: 22023628 DOI: 10.2174/157488812799218974]
- 16 **Satija NK**, Singh VK, Verma YK, Gupta P, Sharma S, Afrin F, Sharma M, Sharma P, Tripathi RP, Gurudutta GU. Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine. *J Cell Mol Med* 2009; **13**: 4385-4402 [PMID: 19602034 DOI: 10.1111/j.1582-4934.2009.00857.x]
- 17 **Hong SH**, Gang EJ, Jeong JA, Ahn C, Hwang SH, Yang IH, Park HK, Han H, Kim H. In vitro differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocyte-like cells. *Biochem Biophys Res Commun* 2005; **330**: 1153-1161 [PMID: 15823564 DOI: 10.1016/j.bbrc.2005.03.086]
- 18 **Piryaei A**, Valojerdi MR, Shahsavani M, Baharvand H. Differentiation of bone marrow-derived mesenchymal stem cells into hepatocyte-like cells on nanofibers and their transplantation into a carbon tetrachloride-induced liver fibrosis model. *Stem Cell Rev* 2011; **7**: 103-118 [PMID: 20182823 DOI: 10.1007/s12015-010-9126-5]
- 19 **Pan Q**, Fouraschen SM, Kaya FS, Verstegen MM, Pescatori M, Stubbs AP, van Ijcken W, van der Sloot A, Smits R, Kwekkeboom J, Metselaar HJ, Kazemier G, de Jonge J, Tilanus HW, Wagemaker G, Janssen HL, van der Laan LJ. Mobilization of hepatic mesenchymal stem cells from human liver grafts. *Liver Transpl* 2011; **17**: 596-609 [PMID: 21506248. DOI: 10.1002/lt.22260]
- 20 **Jung KH**, Shin HP, Lee S, Lim YJ, Hwang SH, Han H, Park HK, Chung JH, Yim SV. Effect of human umbilical cord blood-derived mesenchymal stem cells in a cirrhotic rat model. *Liver Int* 2009; **29**: 898-909 [PMID: 19422480 DOI: 10.1111/j.1478-3231.2009.02031.x]
- 21 **Yamamoto Y**, Banas A, Murata S, Ishikawa M, Lim CR, Teratani T, Hatada I, Matsubara K, Kato T, Ochiya T. A comparative analysis of the transcriptome and signal pathways in hepatic differentiation of human adipose mesenchymal stem cells. *FEBS J* 2008; **275**: 1260-1273 [PMID: 18318837 DOI: 10.1111/j.1742-4658.2008.06287.x]
- 22 **Tsai PC**, Fu TW, Chen YM, Ko TL, Chen TH, Shih YH, Hung SC, Fu YS. The therapeutic potential of human umbilical mesenchymal stem cells from Wharton's jelly in the treatment of rat liver fibrosis. *Liver Transpl* 2009; **15**: 484-495 [PMID: 19399744 DOI: 10.1002/lt.21715]
- 23 **Ricciardi M**, Malpeli G, Bifari F, Bassi G, Pacelli L, Nwabo Kamdje AH, Chilosi M, Krampera M. Comparison of epithelial differentiation and immune regulatory properties of mesenchymal stromal cells derived from human lung and bone marrow. *PLoS One* 2012; **7**: e35639 [PMID: 22567106 DOI: 10.1371/journal.pone.0035639]
- 24 **Li TZ**, Kim JH, Cho HH, Lee HS, Kim KS, Lee SW, Suh H. Therapeutic potential of bone-marrow-derived mesenchymal stem cells differentiated with growth-factor-free coculture method in liver-injured rats. *Tissue Eng Part A* 2010; **16**: 2649-2659 [PMID: 20367252 DOI: 10.1089/ten.TEA.2009.0814]
- 25 **Jung KH**, Shin HP, Lee S, Lim YJ, Hwang SH, Han H, Park HK, Chung JH, Yim SV. Effect of human umbilical cord blood-derived mesenchymal stem cells in a cirrhotic rat model. *Liver Int* 2009; **29**: 898-909 [PMID: 19422480 DOI: 10.1111/j.1478-3231.2009.02031.x]

**P- Reviewer:** Julie NL, Sun BC **S- Editor:** Qi Y **L- Editor:** Wang TQ **E- Editor:** Ma YJ





Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>



ISSN 1007-9327



9 771007 932045